- $3.01bn
- $3.13bn
- $2.35bn
- 99
- 51
- 64
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19 | ||
| PEG Ratio (f) | 0.64 | ||
| EPS Growth (f) | 42.05% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.65 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 14.05 | ||
| Price to Sales | 1.28 | ||
| EV to EBITDA | 20.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.82% | ||
| Return on Equity | 3.93% | ||
| Operating Margin | 4.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,071.52 | 2,214.11 | 2,223.2 | 2,236.38 | 2,348.32 | 2,451.25 | 2,573.46 | 3.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +18.43 | +35.33 | -42.06 | -35.63 | +11.72 | +64.86 | +9.56 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amedisys, Inc. is a healthcare services company. It provides in-home healthcare and related services to the chronic, co-morbid and aging American population. Its segments include home health, hospice and high acuity care. Its home health segment delivers a range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Its nurses administer medications, care for wounds, monitor vital signs and provide a range of other nursing services. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility care to patients in their homes. It owns and operates 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers and eight admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.
Directors
- Paul Kusserow CHM (59)
- Christopher Gerard PRE (54)
- Scott Ginn CFO (52)
- Sharon Brunecz CHO (54)
- Michael North CIO (56)
- Denise Bohnert CCO (43)
- David Kemmerly OTH (58)
- Richard Lechleiter LED (62)
- Vickie Capps IND (59)
- Molly Coye IND (73)
- Julie Klapstein IND (66)
- Teresa Kline IND (62)
- Bruce Perkins IND (67)
- Jeffrey Rideout IND (59)
- Ivanetta Samuels IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 28th, 1994
- Public Since
- August 17th, 1994
- No. of Shareholders
- 444
- No. of Employees
- 19,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 32,810,291
- Address
- 3854 American Way, Suite A, BATON ROUGE, 70816
- Web
- https://www.amedisys.com/
- Phone
- +1 2252922031
- Contact
- Nick Muscato
- Auditors
- KPMG LLP
Upcoming Events for AMED
Q2 2025 Amedisys Inc Earnings Release
Similar to AMED
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
Brightspring Health Services
NASDAQ Global Select Market
FAQ
What is the Amedisys share price?
As of Today at 19:13 UTC, shares in Amedisys are trading at $91.76. This share price information is delayed by 15 minutes.
How has the Amedisys share price performed this year?
Shares in Amedisys last closed at $91.76 and the price had moved by +0.88% over the past 365 days. In terms of relative price strength the Amedisys share price has underperformed the S&P500 Index by -5.14% over the past year.
What are the analyst and broker recommendations for Amedisys?
The overall consensus recommendation for Amedisys is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Amedisys dividend yield?
Amedisys does not currently pay a dividend.
Does Amedisys pay a dividend?
Amedisys does not currently pay a dividend.
When does Amedisys next pay dividends?
Amedisys does not currently pay a dividend.
How do I buy Amedisys shares?
To buy shares in Amedisys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amedisys?
As of the previous close price of $91.76, shares in Amedisys had a market capitalisation of $3.01bn.
Where are Amedisys shares listed?
Here are the trading details for Amedisys:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMED
What kind of share is Amedisys?
Based on an overall assessment of its quality, value and momentum Amedisys is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amedisys share price forecast for 2025?
The analyst consensus target price for shares in Amedisys is $96.17. That is 4.81% above the last closing price of $91.76.
Analysts covering Amedisys currently have a consensus Earnings Per Share (EPS) forecast of $4.70 for the next financial year.
Find out moreWhat is the trend in the Amedisys share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amedisys. Over the past six months, its share price has outperformed the S&P500 Index by +4.3%.
As of the last closing price of $91.76, shares in Amedisys were trading -2.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amedisys PE Ratio?
The Amedisys PE ratio based on its reported earnings over the past 12 months is 19. The shares last closed at $91.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amedisys?
Amedisys' management team is headed by:
- Paul Kusserow - CHM
- Christopher Gerard - PRE
- Scott Ginn - CFO
- Sharon Brunecz - CHO
- Michael North - CIO
- Denise Bohnert - CCO
- David Kemmerly - OTH
- Richard Lechleiter - LED
- Vickie Capps - IND
- Molly Coye - IND
- Julie Klapstein - IND
- Teresa Kline - IND
- Bruce Perkins - IND
- Jeffrey Rideout - IND
- Ivanetta Samuels - IND